Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvon Protection Regulatory News (AVON)

Share Price Information for Avon Protection (AVON)

Share Price is delayed by 15 minutes
Get Live Data
1,678.00    20.00 (1.21%)
Bid:
1,676.00
Ask:
1,680.00
Spread: 4.00 (0.239%)
Market Cap: £494.20m
AVON Live PriceLast checked at - London Stock Exchange

Intraday Avon Protection Share Chart

Post Close Trading Update

13 Oct 2021 07:00

RNS Number : 8651O
Avon Protection PLC
13 October 2021
 

13 October 2021

Avon Protection plc

Post Close Trading Update

 

Avon Protection plc ("Avon" or the "Group") today provides the following post close trading update for its financial year ended 30 September 2021 ("FY21").

 

Trading update

Avon has continued to see good commercial momentum in the second half of FY21, with order intake for the year of c.$280 million. This represents total year-on-year order growth of 34% and growth of 15% excluding Team Wendy. As a result, the Group has carried a strong closing order book of $141 million into the new financial year ("FY22"), up 39% on 30 September 2020. This momentum underpins confidence in the Group's growth expectations for FY22.

 

The Group expects to report revenue of $250 million for FY21 (2020: $213.6 million), which is within the range indicated in our trading update of 13 August 2021. This includes a Team Wendy contribution of $41 million from the first 11 months of ownership, in line with expectations at the time of acquisition.

 

As expected, we have seen revenue growth in our First Responder business and Military respiratory portfolio, offset by declines in Military ballistic revenue due to the previously announced delays. Overall, Military revenue is expected to decline by 3% to $149 million with respiratory revenue growth of 10% being offset by a 31% decline in Military ballistic revenues. First Responder revenues are expected to have increased by 2% to $61 million, against a strong comparator in 2020, driven by very encouraging growth in our ballistic protection portfolio.

 

Trading profitability in the remainder of FY21 was in line with the expectations set out in the August trading update. The Group will however recognise one-off, non-cash, ballistic protection inventory adjustments, which are expected to reduce the reported adjusted EBITDA margin for FY21 to between 15% and 16%.

 

Cash conversion has come through more strongly than anticipated at the time of the August trading update. As a result, we expect FY21 reported cash conversion of c.80% and net debt before lease liabilities of $27 million at 30 September 2021.

 

Commenting, Paul McDonald, Chief Executive Officer, said:

"We have made considerable commercial progress over the last 12 months in continuing to build a broader portfolio of contracts, increasing our pipeline of opportunities and making record levels of investment in the business.

 

We carry significant commercial momentum into FY22, which will also benefit from a strong ramp-up in body armor, as well as the strengthened senior management, processes and infrastructure we have put in place over the past year whilst navigating the ongoing disruption related to Covid through our supply chains.

 

We remain well set for growth in FY22 and beyond and are as confident as ever about the medium-term prospects of Avon Protection. This is underpinned by a strong order book, a growing and visible contract pipeline and our global market leading positions in respiratory and ballistic protection."

 

Notice of Results

The Group will release its results for the year ended 30 September 2021 on 23 November 2021.

 

For further enquiries, please contact:

 

Avon Protection plc

Paul McDonald, Chief Executive Officer

01225 896 848

Nick Keveth, Chief Financial Officer

Rachel Stevens, Director of Investor Relations

MHP Communications

Andrew Jaques

0203 128 8570

Charlie Barker

avonprotection@mhpc.com

Pete Lambie

 

Legal Entity Identifier: 213800JM1AN62REBWA71

Certain information contained in this announcement would have constituted inside information (as defined by Article 7 of Regulation (EU) No 596/2014) ("MAR") prior to its release as part of this announcement and is disclosed in accordance with the Company's obligations under Article 17 of those Regulations.

Note to editors: 

Avon Protection plc is listed on the London Stock Exchange (LSE: AVON) and is an innovative technology group, which designs and produces life critical personal protection systems to maximise the performance and capabilities of its customers, with leading positions in the respiratory and ballistic protection markets for the world's militaries and first responders.

For further information, please visit our website www.avon-protection-plc.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFETIDLFLIL
Date   Source Headline
13th May 20267:00 amRNSInterim Results
8th May 20267:00 amRNSHolding(s) in Company
6th May 20262:03 pmRNSDirector/PDMR Shareholding
28th Apr 20267:00 amRNSHolding(s) in Company
14th Apr 20267:00 amRNSNotice of Results and Investor Presentation
8th Apr 202612:15 pmRNSHolding(s) in Company
8th Apr 202611:47 amRNSDirector/PDMR Shareholding
27th Mar 20261:23 pmRNSDirector/PDMR Shareholding
6th Mar 20261:23 pmRNSDirectors'/PDMR Shareholdings
6th Mar 20267:00 amRNSNew Filter Order
3rd Mar 20262:34 pmRNSHolding(s) in Company
13th Feb 202611:01 amRNSDirector/PDMR Shareholding
6th Feb 20262:52 pmRNSDirectors'/PDMR Shareholdings
6th Feb 20262:41 pmRNSFinal Dividend Currency Exchange Rate
4th Feb 20264:18 pmRNSHolding(s) in Company
2nd Feb 202610:10 amRNSResult of AGM
30th Jan 20267:00 amRNSAGM & Q1 Trading Update
20th Jan 20263:19 pmRNSDirector/PDMR Shareholding
6th Jan 20261:46 pmRNSDirectors'/PDMR Shareholdings
23rd Dec 20259:21 amRNSDirector/PDMR Shareholding
23rd Dec 20259:21 amRNSDirector/PDMR Shareholding
16th Dec 20258:45 amRNSHolding(s) in Company
11th Dec 20253:51 pmRNSHolding(s) in Company
11th Dec 20257:00 amRNSEuropean FM50 Order
9th Dec 202511:58 amRNSDirectors'/PDMR Shareholding
8th Dec 20251:32 pmRNSDirectors'/PDMR Shareholdings
5th Dec 20259:00 amRNSNotice of Annual Report & Accounts and AGM 2026
1st Dec 20256:01 pmRNSDirector Declaration
25th Nov 20253:55 pmRNSHolding(s) in Company
21st Nov 20259:50 amRNSNotification of LTIP & DSBP Awards
12th Nov 20257:00 amRNSPreliminary Results
7th Nov 20259:23 amRNSDirectors'/PDMR Shareholdings
16th Oct 20257:00 amRNSNotice of Results & Investor Presentation via IMC
8th Oct 202510:06 amRNSDirectors'/PDMR Shareholding
15th Sep 20252:51 pmRNSHolding(s) in Company
11th Sep 20254:10 pmRNSHolding(s) in Company
8th Sep 20251:14 pmRNSDirectors'/PDMR Shareholding
13th Aug 20254:59 pmRNSInterim Dividend Currency Exchange Rate
11th Aug 20254:47 pmRNSHolding(s) in Company
7th Aug 20253:10 pmRNSDirectors'/PDMR Shareholdings
17th Jul 20257:00 amRNSDirectors'/PDMR Shareholdings
23rd Jun 20257:00 amRNSUK MoD respirator order for Ukraine
10th Jun 20257:00 amRNSHolding(s) in Company
9th Jun 20259:30 amRNSDirectors'/PDMR Shareholdings
5th Jun 20253:31 pmRNSUS Department of Defense Order
3rd Jun 20256:00 pmRNSRenewi
29th May 202510:00 amRNSHolding(s) in Company
21st May 20257:00 amRNSInterim Results
20th May 20254:00 pmRNSNotification of change in particulars of director
16th May 20253:00 pmRNSNotification of change in particulars of director

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.